Scope
This AAD focused update adds newer topical and biologic options for adults with atopic dermatitis. The available recommendation highlights state the strength of support but do not supply a complete treatment-selection pathway.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
New topical options
- The update gives strong evidence-based support to tapinarof cream and roflumilast cream for managing atopic dermatitis in adults. [1]
New biologic options
- Lebrikizumab also receives a strong evidence-based recommendation for adult atopic dermatitis. Nemolizumab has the same recommendation strength when used with concomitant topical therapy. [1]
Limitations and use
- This is a focused recommendation highlight, not the complete atopic-dermatitis guideline.
- Detailed eligibility, doses, comparative selection, monitoring and subgroup exceptions are not provided by this extract.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Atopic dermatitis in adults: focused treatment update — focused recommendation source
Selected recommendation material consulted
Publication details
- Issuing organisation
- AAD
- Resource type
- Clinical practice guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.